<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="46625">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02499263</url>
  </required_header>
  <id_info>
    <org_study_id>P15-346</org_study_id>
    <nct_id>NCT02499263</nct_id>
  </id_info>
  <brief_title>A Prospective Non-interventional Multicentre Study to Evaluate the Effectiveness of Adalimumab in Korean Patients With Ulcerative Colitis (UC) and Identify Potential Predictors of Clinical Response in Routine Clinical Practice</brief_title>
  <acronym>EUREKA</acronym>
  <official_title>A Prospective Non-interventional Multicentre Study to Evaluate the Effectiveness of Adalimumab in Korean Patients With Ulcerative Colitis (UC) and Identify Potential Predictors of Clinical Response in Routine Clinical Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single country, multi-center study in Ulcerative Colitis (UC)
      patients treated with adalimumab. 200 subjects will be enrolled at approximately 20 sites.
      The baseline assessment should be performed prior to the first dose of adalimumab (Visit1).
      Study visits will be conducted at weeks 8, 16, 24, 32, 40, 48 and 56 in accordance with
      clinical practice. All subjects will have one Follow-up for safety approximately 70 days
      after the last dose of adalimumab
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is Observation study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects with clinical response at week 8</measure>
    <time_frame>At week 8</time_frame>
    <description>Assessing percentage of subjects with clinical response which is defined as reduction in complete Mayo score of ≥ 3 points and ≥ 30% from Week 0 with an accompanying decrease in rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point at week 8.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with clinical response in week 8 responders</measure>
    <time_frame>At week 56</time_frame>
    <description>Assessing subjects with durable clinical response which is defined as reduction in complete Mayo score of ≥ 3 points and ≥ 30% from Week 0 with an accompanying decrease in rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore o ≤ 1 point at week 56 in week 8 responders.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with clinical remission in week 8 responders</measure>
    <time_frame>At week 56</time_frame>
    <description>Assessing percentage of subjects with clinical remission which is defined as a total Mayo score &lt;=2 points, with no individual sub-score exceeding 1 point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with steroid-free remission in week 8 responders</measure>
    <time_frame>At week 56</time_frame>
    <description>Assessing subjects with steroid free remission which is defined as patients who are in remission without the use of systemic steroids within the past 12 weeks prior to assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with mucosal healing in week 8 responders</measure>
    <time_frame>At week 56</time_frame>
    <description>Assessing percentage of subjects with mucosal healing which is defined as an endoscopy sub-score of 0 or 1. Endoscopic findings were scored on a scale from 0 to 3 as follows: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern, mild friability); 2 = Moderate disease (marked erythema, lack of vascular pattern, friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of partial Mayo score</measure>
    <time_frame>From week 0 to week 56</time_frame>
    <description>Partial Mayo score will be measured at Week 16 , 24, 32, 40 and Week 48. The change from week 0 (baseline) overtime will be described statistically.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the composition of Fecal micro biota</measure>
    <time_frame>From week 0 to week 56</time_frame>
    <description>Composition of Fecal microbiota (16S ribosomal ribonucleic acid (rRNA) gene sequencing) will be measured at week 0, week 8, and week 56. The change from week 0 (baseline) overtime will be described statistically</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change of Fecal calprotectin level</measure>
    <time_frame>From week 0 to week 56</time_frame>
    <description>Fecal calprotectin will be measured at week 0, week 8 and week 56. The change from week 0 (baseline) overtime will be described statistically.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">147</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Subjects with Ulcerative Colitis</arm_group_label>
    <description>Subject with active moderate-to-severe ulcerative colitis patients with Mayo score of ≥6 points and endoscopic sub-score of ≥2 points despite treatment with corticosteroids and/or immunosuppressants.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Fecal samples : Fecal calprotectin and the composition of Fecal microbiota Blood samples :
      Trough level of adalimumab &amp; Antibodies against adalimumab
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        General Hospital
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must be an adult &gt;= 19 years

          -  Subject with active moderate-to-severe ulcerative colitis patients with Mayo score of
             ≥ 6 points and endoscopic sub-score of &gt;= 2 points despite treatment with
             corticosteroids and/or immunosuppressants

          -  Subjects must have tuberculosis (TB) Screening Assessment in accordance Korean
             reimbursement guideline

          -  Subjects who are started on adalimumab treatment in normal clinical practice setting

          -  Subject must provide written authorization form to use personal and/or health data
             prior to the entry into the study

        Exclusion Criteria:

          -  Female subjects who are pregnant or breast feeding

          -  Subject applies with any contraindication to adalimumab

          -  Subject is participating in other clinical trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>EunJung Gu</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>SuKyung Kim</last_name>
    <phone>+82 2 3429 9235</phone>
    <email>sukyung.kim@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EunJung Gu</last_name>
    <phone>+82 2 3429 9399</phone>
    <email>eunjung.gu@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138451</name>
      <address>
        <city>Busan</city>
        <zip>47392</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 138451, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138447</name>
      <address>
        <city>Daegu</city>
        <zip>41931</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 153133</name>
      <address>
        <city>Daegu</city>
        <zip>41944</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 153133, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138445</name>
      <address>
        <city>Daejeon</city>
        <zip>301-723</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 138445, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138442</name>
      <address>
        <city>Guri</city>
        <zip>471-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 138442, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138454</name>
      <address>
        <city>Gwangju</city>
        <zip>501-717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 138454, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138450</name>
      <address>
        <city>Gwangju</city>
        <zip>61469</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 138450, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 150176</name>
      <address>
        <city>Incheon</city>
        <zip>400-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 150176, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138446</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 138446, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138456</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 138456, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138449</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 138449, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138452</name>
      <address>
        <city>Seoul</city>
        <zip>100-032</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 138452, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138443</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 138443, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 150175</name>
      <address>
        <city>Seoul</city>
        <zip>110-746</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 150175, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138453</name>
      <address>
        <city>Seoul</city>
        <zip>130-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 138453, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 134689</name>
      <address>
        <city>Seoul</city>
        <zip>135-846</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138448</name>
      <address>
        <city>Seoul</city>
        <zip>156-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 138448, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138441</name>
      <address>
        <city>Seoul</city>
        <zip>156-755</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 138441, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138444</name>
      <address>
        <city>Seoul</city>
        <zip>158-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 138444, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138457</name>
      <address>
        <city>Suwon-si</city>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 138457, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138455</name>
      <address>
        <city>Suwon</city>
        <zip>442-723</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 138455, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://rxabbvie.com/</url>
    <description>Regarding Medicine Information</description>
  </link>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 2, 2017</lastchanged_date>
  <firstreceived_date>July 1, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adalimumab trough level</keyword>
  <keyword>Fecal Calprotectin</keyword>
  <keyword>Fecal microbiota</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Colitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
